Related Experiment Video
Updated: Dec 18, 2025

Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
Published on: April 25, 2025
[Behçet's Syndrome]
Theodoros Xenitidis1, Joerg Christoph Henes1
1Abteilung und Lehrstuhl II, Hämatologie/Onkologie/klinische Immunologie/Rheumatologie, Medizinische Universitätsklinik, Universitätsklinikum Tübingen.
Insights
Behçet
Area of Science:
- Rheumatology and Immunology
- Vascular Medicine
Background:
- Behçet's syndrome (BS) is a complex vasculitis with diverse clinical manifestations.
- Its pathogenesis bridges polygenic autoinflammatory and autoimmune disease characteristics.
- Recent EULAR recommendations (2018) guide management strategies.
Purpose of the Study:
- To provide an overview of Behçet's syndrome classification and pathogenesis.
- To highlight current therapeutic approaches based on affected organs.
- To discuss recent advancements in BS treatment.
Main Methods:
- Review of current literature and clinical guidelines for Behçet's syndrome.
- Analysis of pathogenetic mechanisms.
- Evaluation of therapeutic options including biologics and targeted therapies.
Main Results:
- Behçet's syndrome is a variable vessel vasculitis requiring multidisciplinary care.
- Adalimumab is approved for posterior ocular involvement since 2016.
- Alternative therapies include infliximab, interferon alfa-2a, IL-1 antagonists, and apremilast.
Conclusions:
- Therapeutic decisions in Behçet's syndrome are guided by organ involvement.
- Targeted therapies like adalimumab offer new treatment avenues.
- Ongoing research aims to further elucidate pathogenesis and optimize treatment protocols.
Abstract:
Behçet's syndrome (BS) is classified as a variable vessel vasculitis. The clinical picture is very diverse and usually requires interdisciplinary collaboration. Pathogenetically, BS seems to take a middle position between a polygenic autoinflammatory disease and an autoimmune disease. New EULAR recommendations were issued in 2018. The therapy depends on which organs are most affected. Since 2016, adalimumab has been approved for the treatment of posterior ocular involvement. Infliximab, interferon a2a, interleukin-1 antagonists and apremilast may be alternative therapies.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Endocarditis II: Clinical Features of Infective Endocarditis
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Nephrotic Syndrome III : Nursing Management
Pericarditis II: Clinical Features and Diagnostic Tests

